2023
Comorbid alcohol use disorder and posttraumatic stress disorder: A proof‐of‐concept randomized placebo‐controlled trial of buprenorphine and naltrexone combination treatment
Davis L, Petrakis I, Pilkinton P, Nolen T, Vandergrift N, Hirsch S, Norrholm S, Kosten T. Comorbid alcohol use disorder and posttraumatic stress disorder: A proof‐of‐concept randomized placebo‐controlled trial of buprenorphine and naltrexone combination treatment. Alcohol Clinical And Experimental Research 2023, 47: 1756-1772. PMID: 37468230, DOI: 10.1111/acer.15155.Peer-Reviewed Original ResearchComorbid alcohol use disorderAlcohol use disorderPosttraumatic stress disorderPlacebo-controlled trialWorld Health OrganizationReceptor antagonismOpioid receptorsUse disordersExtended-release injectable naltrexoneKappa-opioid receptor antagonistStress disorderClinician-Administered PTSD ScalePrimary composite outcomeEffective pharmacologic treatmentOpioid receptor antagonistOpioid receptor antagonismMu-opioid receptorsCombination of buprenorphineBinary primary outcomeTimeline Follow-BackAUD outcomesBuprenorphine 2Injectable placeboPrimary timepointInjectable naltrexone
2017
Randomized Clinical Trial of a Combination of an Inhaled Corticosteroid and Beta Agonist in Patients at Risk of Developing the Acute Respiratory Distress Syndrome*
Festic E, Carr G, Cartin-Ceba R, Hinds R, Banner-Goodspeed V, Bansal V, Asuni A, Talmor D, Rajagopalan G, Frank R, Gajic O, Matthay M, Levitt J. Randomized Clinical Trial of a Combination of an Inhaled Corticosteroid and Beta Agonist in Patients at Risk of Developing the Acute Respiratory Distress Syndrome*. Critical Care Medicine 2017, 45: 798-805. PMID: 28240689, PMCID: PMC5392150, DOI: 10.1097/ccm.0000000000002284.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdministration, InhalationAdrenal Cortex HormonesAdrenergic beta-AgonistsAgedAged, 80 and overBiomarkersBudesonide, Formoterol Fumarate Drug CombinationDouble-Blind MethodDrug Therapy, CombinationFemaleHumansHypoxiaMaleMiddle AgedOxygenPatient AcuityRespiration, ArtificialRespiratory Distress SyndromeRisk FactorsUnited StatesConceptsAcute respiratory distress syndromeRespiratory distress syndromeBudesonide/formoterolDistress syndromeBeta agonistsMore patientsMechanical ventilationClinical trialsEarly treatmentFirst study drugAlveolar fluid clearanceEffective pharmacologic treatmentRandomized clinical trialsPlacebo bidCategorical changePlacebo groupStudy drugAdult patientsLung inflammationLung injuryPharmacologic treatmentPrimary outcomeMedian timeEmergency departmentImproved oxygenation
2007
Prevention of liver fibrosis by the purinoceptor antagonist pyridoxal-phosphate-6-azophenyl-2',4'-disulfonate (PPADS).
Dranoff JA, Kruglov EA, Abreu-Lanfranco O, Nguyen T, Arora G, Jain D. Prevention of liver fibrosis by the purinoceptor antagonist pyridoxal-phosphate-6-azophenyl-2',4'-disulfonate (PPADS). In Vivo 2007, 21: 957-65. PMID: 18210741.Peer-Reviewed Original ResearchConceptsHepatic stellate cellsBile duct ligationLiver fibrosisDuct ligationPurinergic receptorsCommon bile duct ligationEffect of PPADSPurinergic receptor inhibitorsDevelopment of cirrhosisHSC proliferationEffective pharmacologic treatmentExperimental liver fibrosisAnnexin V flow cytometryEffect of suraminSirius red stainQuantitative RT-PCRPharmacologic treatmentReceptor inhibitorsPPADSStellate cellsLiver sectionsFibrosisBromodeoxyuridine uptakePurinoceptor activationExperimental animals
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply